Pfizer Announces Topline Phase 3 Results for Sigvotatug Vedotin in Previously Treated Metastatic Non-Squamous Non-Small Cell Lung Cancer

Phase 3sigvotatug vedotinNeutral

AI Analysis

Summary

Pfizer announced topline Phase 3 results from the SigVie-002 study evaluating sigvotatug vedotin in previously treated metastatic non-squamous non-small cell lung cancer. The article contains limited detail regarding trial outcomes or endpoints.

Clinical Trial Data

Phase

Phase 3

Importance:7/10

Sentiment:

0.00

Phase 3topline resultslung canceroncology

Related Companies

$PFE

Read the original article

Published by Drugs.com Clinical Trial Results on July 2, 2026 8:07 AM

Read Original